Kurma Biofund I, with a size of 51 million euros, was launched in November 2009. It comprises a portfolio of 11 active Life Sciences companies. Five companies out of this portfolio has been created by the Fund in collaboration with research Institutes.
Kurma Partners bases its TT investment strategy on the following principles :
The purpose of Kurma Biofund II is to invest in projects and Companies in the Life Sciences sector, essentially in Europe but to a marginal extent also in the US, that address a significant medical need.
At least 50% of Kurma Biofund II investments will be directly or indirectly devoted to orphan diseases. These projects will largely concern therapeutic programmes, primarily or secondarily targeting rare diseases and responding to a strong medical need. In general, they will involve the development of new drugs up to clinical proof of concept. Kurma Biofund II began its investment period in June 2013
Kurma Diagnostics (KDx) is a acceleration funds that is wholly focused on Diagnostics, Patient monitoring, and e-Health initiatives.
The fund is around 35 million euros in size, and can invest in newly formed companies, or projects that are developing applications that radically alter the current standard solutions.
The main investors of KDx are BPI France, the European Investment Fund, BNP-Paribas, and the Pasteur Institute, the latter being a strategic partner with the fund.
More than 10 major European academic institutes are closely associated with KDx.
The "Idinvest Biotech" portfolio was constituted between 2004 and 2010. It is made up of 14 companies based in France, Great Britain, Denmark, Switzerland and Benelux. These companies operate in the field of human health, in emerging and niche markets which particularly concern orphan diseases, children's diseases, medical diagnosis and theranostics.